Modulation of Butyrate Anticancer Activity by Solid Lipid Nanoparticle Delivery: An in Vitro Investigation on Human Breast Cancer and Leukemia Cell Lines

Foglietta, Federica; Serpe, Loredana; Canaparo, Roberto; Vivenza, Nicoletta; Riccio, Giovanna; Imbalzano, E.; Gasco, Paolo; Zara, Gian Paolo

doi:10.18433/j3xp4r

Cited by 29 publications

(20 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CLSM analysis indicated that without NaBu, FRs were more expressed on the cells treated with FA-PEG@MNP, whereas, in the presence of NaBu no differences were observed between the cells treated with FA-PEG@MNP and PEG@MNP. It was probable that these effects were due to the differentiation induced by NaBu that led to a similar uptake of both MNP types [39]. These results accounted for the similar cell uptake observed for both types of MNPs in the presence of NaBu.…”

Section: Int J Mol Sci 2020 21 X For Peer Review 9 Of 16supporting

confidence: 56%

“…We showed that the contemporary exposure of adenocarcinoma cells to NaBu and to MNPs either with or without FA caused a strong decrease of LoVo cell viability, whereas an equal expression of FRs was highlighted. It is likely these effects are due to the differentiation induced by butyrate that leads to a similar uptake of both MNP types [39]. In addition, our findings indicate that folate in the coating or used as a free formulation can modulate the cytotoxic action of NaBu.…”

Section: Discussionmentioning

confidence: 60%

See 1 more Smart Citation

The Interplay between Fe3O4 Superparamagnetic Nanoparticles, Sodium Butyrate, and Folic Acid for Intracellular Transport

Cambria

Villaggio

Laudani

et al. 2020

IJMS

View full text Add to dashboard Cite

Combined treatments which use nanoparticles and drugs could be a synergistic strategy for the treatment of a variety of cancers to overcome drug resistance, low efficacy, and high-dose-induced systemic toxicity. In this study, the effects on human colon adenocarcinoma cells of surface modified Fe3O4 magnetic nanoparticles (MNPs) in combination with sodium butyrate (NaBu), added as a free formulation, were examined demonstrating that the co-delivery produced a cytotoxic effect on malignant cells. Two different MNP coatings were investigated: a simple polyethylene glycol (PEG) layer and a mixed folic acid (FA) and PEG layer. Our results demonstrated that MNPs with FA (FA-PEG@MNPs) have a better cellular uptake than the ones without FA (PEG@MNPs), probably due to the presence of folate that acts as an activator of folate receptors (FRs) expression. However, in the presence of NaBu, the difference between the two types of MNPs was reduced. These similar behaviors for both MNPs likely occurred because of the differentiation induced by butyrate that increases the uptake of ferromagnetic nanoparticles. Moreover, we observed a strong decrease of cell viability in a NaBu dose-dependent manner. Taking into account these results, the cooperation of multifunctional MNPs with NaBu, taking into consideration the particular cancer-cell properties, can be a valuable tool for future cancer treatment.

show abstract

Section: Int J Mol Sci 2020 21 X For Peer Review 9 Of 16supporting

confidence: 56%

Section: Discussionmentioning

confidence: 60%

The Interplay between Fe3O4 Superparamagnetic Nanoparticles, Sodium Butyrate, and Folic Acid for Intracellular Transport

Cambria

Villaggio

Laudani

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…SLC5A8 was selected because it was recently identified as a cancer suppressor gene and because previous studies related downregulation of this gene to the progression of various types of cancer, including gastric (Ueno et al, 2004 ), colonic (Li et al, 2003 ; Thangaraju et al, 2008 ; Brim et al, 2011 ), thyroid (Porra et al, 2005 ), and breast cancers (Foglietta et al, 2014 ).…”

Section: Methodsmentioning

confidence: 99%

Helicobacter pylori Infection Is Associated with Decreased Expression of SLC5A8, a Cancer Suppressor Gene, in Young Children

Orellana‐Manzano

O’Ryan

Lagomarcino

et al. 2016

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Background: Helicobacter pylori infects half of the world's population and causes gastric cancer in a subset of infected adults. Previous blood microarray findings showed that apparently healthy children, persistently infected with H. pylori have differential gene expression compared to age-matched, non-infected children. SLC5A8, a cancer suppressor gene with decreased expression among infected children, was chosen for further study based on bioinformatics analysis.Methods: A pilot study was conducted using specific qRT-PCR amplification of SLC5A8 in blood samples from H. pylori infected and non-infected children, followed by a larger, blinded, case-control study. We then analyzed gastric tissue from H. pylori infected and non-infected children undergoing endoscopy for clinical purposes.Results: Demographics, clinical findings, and family history were similar between groups. SLC5A8 expression was decreased in infected vs. non-infected children in blood, 0.12 (IQR: 0–0.89) vs. 1.86 (IQR: 0–8.94, P = 0.002), and in gastric tissue, 0.08 (IQR: 0.04–0.15) vs. 1.88 (IQR: 0.55–2.56; P = 0.001). Children who were both stool positive and seropositive for H. pylori had the lowest SLC5A8 expression levels.Conclusions: H. pylori infection is associated with suppression of SCL5A8, a cancer suppressor gene, in both blood and tissue samples from young children.Key Points: Young children, persistently infected with Helicobacter pylori show decreased expression of SLC5A8 mRNA in both blood and tissue samples as compared to non-infected children.

show abstract

“…The use of SLN has been under investigation in various preclinical and clinical trials, especially in cancer therapy, and their employment has been approved for clinical use in some cases[36]. Cholesteryl butyrate (Cb) as a butyrate SLN formulation has been evaluated in several in vitro and in vivo studies as an anticancer agent[37-41] and only in in vitro studies as anti-inflammatory agent[17,42]. …”

Section: Introductionmentioning

confidence: 99%

Solid lipid nanoparticles delivering anti-inflammatory drugs to treat inflammatory bowel disease: Effects in anin vivomodel

Dianzani¹,

Foglietta²,

Ferrara³

et al. 2017

WJG

Self Cite

View full text Add to dashboard Cite

AIMTo improve anti-inflammatory activity while reducing drug doses, we developed a nanoformulation carrying dexamethasone and butyrate.METHODSDexamethasone cholesteryl butyrate-solid lipid nanoparticles (DxCb-SLN) were obtained with the warm microemulsion method. The anti-inflammatory activity of this novel nanoformulation has been investigated in vitro (cell adhesion to human vascular endothelial cells and pro-inflammatory cytokine release by lipopolysaccharide-induced polymorphonuclear cells) and in vivo (disease activity index and cytokine plasma concentrations in a dextran sulfate sodium-induced mouse colitis) models. Each drug was also administered separately to compare its effects with those induced by their co-administration in SLN at the same concentrations.RESULTSDxCb-SLN at the lowest concentration tested (Dx 2.5 nmol/L and Cb 0.1 μmol/L) were able to exert a more than additive effect compared to the sum of the individual effects of each drug, inducing a significant in vitro inhibition of cell adhesion and a significant decrease of pro-inflammatory cytokine (IL-1β and TNF-α) in both in vitro and in vivo models. Notably, only the DxCb nanoformulation administration was able to achieve a significant cytokine decrease compared to the cytokine plasma concentration of the untreated mice with dextran sulfate sodium-induced colitis. Specifically, DxCb-SLN induced a IL-1β plasma concentration of 61.77% ± 3.19%, whereas Dx or Cb used separately induced a concentration of 90.0% ± 2.8% and 91.40% ± 7.5%, respectively; DxCb-SLN induced a TNF-α plasma concentration of 30.8% ± 8.9%, whereas Dx or Cb used separately induced ones of 99.5% ± 4.9% and 71.1% ± 10.9%, respectively.CONCLUSIONOur results indicate that the co-administration of dexamethasone and butyrate by nanoparticles may be beneficial for inflammatory bowel disease treatment.

show abstract

Modulation of Butyrate Anticancer Activity by Solid Lipid Nanoparticle Delivery: An in Vitro Investigation on Human Breast Cancer and Leukemia Cell Lines

Cited by 29 publications

References 55 publications

The Interplay between Fe3O4 Superparamagnetic Nanoparticles, Sodium Butyrate, and Folic Acid for Intracellular Transport

The Interplay between Fe3O4 Superparamagnetic Nanoparticles, Sodium Butyrate, and Folic Acid for Intracellular Transport

Helicobacter pylori Infection Is Associated with Decreased Expression of SLC5A8, a Cancer Suppressor Gene, in Young Children

Solid lipid nanoparticles delivering anti-inflammatory drugs to treat inflammatory bowel disease: Effects in anin vivomodel

Contact Info

Product

Resources

About